Fig. 1From: A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjectsMean Serum Concentration-Time Profiles of Adalimumab Following Subcutaneous Dose of FKB327Back to article page